Dare Bioscience Inc (DARE) Smart Money Holdings (13F, Q2 2026)

DARE ranks #7638 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

28 institutions disclose a position in DARE, but none treat it as a major bet — even Objectivity Squared, LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

DARE reported a net loss of $11.0M over the trailing twelve months.

• Not yet profitable — net loss of $11.0M over the trailing twelve months
• Revenue grew 7816.7% year over year
• Net income improved year over year, from -$18.6M to -$11.0M
• Operating cash flow was negative, using $9.9M in cash
• Current ratio of 1.14x — below the conventional 1.5x liquidity buffer
• Liabilities run 10.42x equity — a highly leveraged balance sheet worth noting